ArticleBMC cardiovascular disorders2025
Association of serum uric acid to high-density lipoprotein cholesterol ratio with all-cause mortality and cardiovascular disease mortality in patients with gout.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe uric acid to high-density lipoprotein cholesterol ratio (UHR), a novel biomarker, has clinical value in diagnosing and evaluating metabolic syndrome, diabetes mellitus, and atherosclerosis. However, the relationship between UHR and mortality in gout patients is unknown.This study aimed to investigate UHR's link to all-cause and cardiovascular mortality in gout patients.
methodsBased on NHANES data from 2007 to 2018, 1,479 gout patients who completed follow-up as of December 31, 2018 were included, and patients were divided into four groups using UHR, we analyzed the relationship between UHR and risk of death using Cox regression models, tested for nonlinear relationships with a restricted cubic spline, and assessed for population heterogeneity by stratifying by sex, age, and body mass index.
resultsThe Kaplan-Meier analysis revealed that patients in the third UHR quartile (Q3) had the highest risk of death. The multivariate Cox regression analysis further confirmed that the overall mortality risk (HR: 1.44, 95% CI: 1.05-1.97) and cardiovascular mortality risk (HR: 1.73, 95% CI: 1.04-2.87) of this group were higher than those of the other groups. Restricted cubic spline analysis revealed a U-shaped association between UHR and all-cause mortality, with a significant positive correlation above a threshold of 21.6% (HR: 1.68, 95% CI: 1.26-2.24) and a linear positive correlation with cardiovascular mortality (HR: 1.40, 95% CI: 1.05-1.86). Subgroup analyses showed that these associations were consistent across age, BMI, and sex (p > 0.05 for interaction).
conclusionThis study confirms that UHR in gout patients has a U-shaped correlation with all-cause mortality and a linear correlation with cardiovascular mortality. Therefore, UHR may serve as a novel prognostic biomarker for mortality risk stratification in patients with gout.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.